Nuveen
PCVX icon

Nuveen’s Vaxcyte PCVX Stock Holding History

Nuveen’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9M Buy
324,762
+3,973
+1% +$216K ﹤0.01% 1300
2026
Q1 		$18.6M Buy
320,789
+13,587
+4% +$738K 0.01% 1173
2025
Q4 		$14.2M Sell
307,202
-177,436
-37% -$7.94M ﹤0.01% 1359
2025
Q3 		$17.5M Sell
484,638
-3,131
-0.6% -$104K ﹤0.01% 1234
2025
Q2 		$15.9M Sell
487,769
-68,063
-12% -$2.23M ﹤0.01% 1242
2025
Q1 		$21M Buy
555,832
+26,182
+5% +$2.09M 0.01% 1105
2024
Q4 		$43.4M Buy
529,650
+65,713
+14% +$6.53M 0.01% 712
2024
Q3 		$53M Buy
463,937
+138,776
+43% +$12.5M 0.01% 629
2024
Q2 		$24.6M Buy
325,161
+13,809
+4% +$940K 0.01% 1004
2024
Q1 		$21.3M Buy
311,352
+30,496
+11% +$2.11M 0.01% 1142
2023
Q4 		$17.6M Sell
280,856
-15,556
-5% -$808K 0.01% 1239
2023
Q3 		$15.1M Buy
296,412
+2,506
+0.9% +$124K 0.01% 1219
2023
Q2 		$14.7M Buy
293,906
+34,688
+13% +$1.64M 0.01% 1278
2023
Q1 		$9.71M Buy
259,218
+2,842
+1% +$121K ﹤0.01% 1501
2022
Q4 		$12.3M Buy
256,376
+66,864
+35% +$2.62M ﹤0.01% 1358
2022
Q3 		$4.55M Buy
189,512
+37,353
+25% +$947K ﹤0.01% 1960
2022
Q2 		$3.31M Buy
152,159
+11,333
+8% +$262K ﹤0.01% 2180
2022
Q1 		$3.48M Sell
140,826
-1,518
-1% -$33.2K ﹤0.01% 2254
2021
Q4 		$2.99M Sell
142,344
-10,637
-7% -$247K ﹤0.01% 2369
2021
Q3 		$3.88M Sell
152,981
-7,855
-5% -$190K ﹤0.01% 2346
2021
Q2 		$3.62M Buy
160,836
+65,143
+68% +$1.33M ﹤0.01% 2408
2021
Q1 		$1.89M Buy
95,693
+22,992
+32% +$579K ﹤0.01% 2645
2020
Q4 		$1.93M Sell
72,701
-4,958
-6% -$184K ﹤0.01% 2528
2020
Q3 		$3.83M Buy
+77,659
New +$3.09M ﹤0.01% 2058

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nuveen's PCVX Position: Q2 2026 in Review

Nuveen increased its Vaxcyte (PCVX) stake by 1.2% in Q2 2026, buying an estimated $216K and bringing the position to 324,762 shares worth $18.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1300.

Nuveen first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. The position peaked at $53M in Q3 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Nuveen held 324,762 shares of Vaxcyte worth $18.9M as of Q2 2026.
  • Nuveen bought 3,973 Vaxcyte shares in Q2 2026, an estimated $216K.
  • Vaxcyte made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1300 holding.
  • Nuveen first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • Nuveen's Vaxcyte position peaked at $53M in Q3 2024.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.